Maze Therapeutics (NASDAQ:MAZE) Shares Gap Down - Time to Sell?

Key Points

• Maze reported positive Phase 2 HORIZON topline data for oral APOL1 inhibitor MZE829, showing a 35.6% mean uACR reduction in the broad AMKD population and 61.8% in the FSGS subgroup, and management plans to advance the asset into a pivotal program.
• Despite the encouraging data, shares gapped down — the stock closed at $49.00 the prior session, opened at $40.00 and traded near $31.10 on heavy volume (~3.26M shares), indicating profit‑taking and heightened volatility.
• Maze also reports a strong cash position (~$360M) with runway into 2028 and added Neil Kumar to the board, steps that reduce near‑term financing risk and strengthen governance as the company readies pivotal trials.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $49.00, but opened at $40.00. Maze Therapeutics shares last traded at $31.0950, with a volume of 3,256,365 shares traded.

Key Headlines Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Maze announced positive topline Phase 2 HORIZON results for oral APOL1 inhibitor MZE829 showing a 35.6% mean uACR reduction in the broad AMKD population at week 12, a 61.8% mean uACR reduction in the FSGS subgroup, strong responses in non‑diabetic patients, a favorable tolerability profile, and plans to advance MZE829 into a pivotal program. This clinical proof‑of‑concept is the primary driver of the earlier rally. Phase 2 HORIZON topline release
• Positive Sentiment: Management added Neil Kumar (founder/CEO of BridgeBio) to the board and flagged two Phase 2 PoC trials for MZE782 (PKU and CKD) expected to start in 2026 — governance and pipeline expansion that investors typically view as supportive of program execution. Board appointment article
• Positive Sentiment: Maze reports a strong cash position (~$360M) with management projecting runway into 2028, reducing near‑term financing risk as they advance MZE829 toward a pivotal program. Financial results & highlights
• Neutral Sentiment: Maze is hosting an investor conference call and webcast (today) to discuss the HORIZON data and next steps — a convening that could add clarity and move the stock depending on management’s pivotal plan details and timeline. Conference call notice
• Neutral Sentiment: Short‑interest data published for March appears to be erroneous or reports no meaningful short position (entries show zero/NaN), so there’s no clear short‑squeeze signal detectable from those items. (Monitor updated short interest filings for accuracy.)
• Negative Sentiment: Maze reported Q4/2025 results showing a GAAP loss per share (EPS of -$0.65) — typical for a clinical‑stage biotech but a reminder of ongoing R&D expense; some of the intraday selling likely reflects profit‑taking and digestion of the company’s cash burn profile despite runway commentary. Earnings release

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on MAZE shares. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Lifesci Capital upgraded shares of Maze Therapeutics to a "strong-buy" rating in a report on Thursday, December 18th. Wedbush lifted their target price on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an "outperform" rating in a report on Monday, March 16th. HC Wainwright upped their price target on Maze Therapeutics from $60.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Mizuho upgraded Maze Therapeutics to a "strong-buy" rating in a research note on Wednesday, March 11th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $64.11.

Maze Therapeutics Price Performance

The firm's 50 day moving average price is $46.16 and its 200-day moving average price is $37.60. The stock has a market cap of $1.62 billion, a P/E ratio of -1.63 and a beta of 4.47.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter.

Insiders Place Their Bets

In other news, SVP Amy Bachrodt sold 10,000 shares of the firm's stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.58, for a total transaction of $405,800.00. Following the sale, the senior vice president owned 12,965 shares of the company's stock, valued at $526,119.70. This trade represents a 43.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Atul Dandekar sold 72,400 shares of the business's stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the transaction, the insider directly owned 10,503 shares of the company's stock, valued at $426,001.68. The trade was a 87.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 245,000 shares of company stock valued at $10,504,792.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its stake in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after buying an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics in the fourth quarter worth $39,000. Ameritas Investment Partners Inc. lifted its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after acquiring an additional 738 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics in the fourth quarter worth about $43,000. Finally, Russell Investments Group Ltd. grew its stake in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after purchasing an additional 1,725 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.